Roche is continuing its buying spree with a deal to acquire Madison, WI-based Mirus Bio for $125 million. Mirus specializes in developing nucleic acid-based therapies, which includes RNAi technology for gene silencing.
"The technology brought by Mirus, together with additional technologies, will bring us closer to creating fully-enabled RNAi therapeutics," said Lee Babiss, global head of Roche pharma research.
- check out the release
- read the report from Hays Pharma